Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERBY: Bevacizumab in pediatric high-grade glioma
NCT01390948Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2011
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in high-grade glioma (HGG) (3 arms), sponsored by Roche. Primary endpoint: Event-Free Survival at 12 months. Started Oct 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT01390948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01390948.